Worldwide Chronic Obstructive Pulmonary Disease Industry to 2030 – Market Insights, Epidemiology and Forecasts – ResearchAndMarkets.com

Kimono R Pablo

DUBLIN–(BUSINESS WIRE)–The “Chronic Obstructive Pulmonary Disease (COPD) – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering. This report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market […]

DUBLIN–(BUSINESS WIRE)–The “Chronic Obstructive Pulmonary Disease (COPD) – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Chronic Obstructive Pulmonary Disease (COPD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic Obstructive Pulmonary Disease (COPD) market size from 2018 to 2030. The Report also covers current Chronic Obstructive Pulmonary Disease (COPD) treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

  • The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease (COPD) in seven major markets was found to be 31,730,590 in 2020 and is anticipated to increase in 2030.
  • The estimates suggest a higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020, which might increase in 2030.
  • The majority of cases of Chronic Obstructive Pulmonary Disease (COPD) are female as compared to male, in the US. But in EU-5 and Japan the diagnosed cases of males represents majority of the cases.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology

The epidemiology segment also provides the Chronic Obstructive Pulmonary Disease (COPD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Key Findings

  • The market size of Chronic Obstructive Pulmonary Disease (COPD) in seven major markets was estimated to be USD 12,134 million in 2020, for the study period (2018-2030).
  • The United States accounts for the largest market size of COPD, in comparison to EU5, and Japan.
  • The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of COPD.
  • Among the EU5 countries, Germany had the highest market size with USD 617 million in 2020, while United kingdom had the lowest market size of COPD with USD 274 million each, in 2020.

Scope of the Report

  • The report covers the descriptive overview of Chronic Obstructive Pulmonary Disease (COPD), explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Chronic Obstructive Pulmonary Disease (COPD) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Obstructive Pulmonary Disease (COPD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Chronic Obstructive Pulmonary Disease (COPD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Chronic Obstructive Pulmonary Disease (COPD) market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Chronic Obstructive Pulmonary Disease (COPD) market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease (COPD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Chronic Obstructive Pulmonary Disease (COPD). The launch of emerging therapies will significantly impact the Chronic Obstructive Pulmonary Disease (COPD) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • Afimmune
  • Amgen
  • AstraZeneca
  • Biomarck Pharmaceuticals
  • Boehringer Ingelheim Pharmaceuticals
  • Chiesi Farmaceutici S.p.A.
  • Circassia Pharmaceuticals Inc.
  • Genentech
  • GlaxoSmithKline
  • Inmunotek
  • Innoviva
  • Mereo BioPharma
  • Novartis Pharmaceuticals
  • Organicell Regenerative Medicine
  • Pulmotect Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sunovion Pharmaceuticals
  • Tetherex Pharmaceuticals Corporation
  • Theravance, Inc
  • United Therapeutics
  • Verona Pharma PLC
  • Vertex Pharmaceuticals Incorporated

For more information about this report visit https://www.researchandmarkets.com/r/ofst1m

Next Post

How Does NRI Trading Account Works in India?

The Indian stock market is one of the most exciting and fascinating platforms to invest in and make tremendous profits. For investors like you, who may have spent years on understanding the Indian stock market, shifting outside India may include the idea of losing your demat account, demat holdings and […]

Subscribe US Now